Cohort Studymoderate evidence
Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women With Vasomotor Symptoms.
JAMA internal medicine·September 8, 2026·PMID 42709460
Why it mattersVasomotor symptoms are linked to future CVD risk, yet most MHT trials have focused on older postmenopausal women. This study addresses a gap by evaluating MHT in symptomatic perimenopausal women, a group where timing and symptom burden may influence cardiovascular outcomes.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled